Krishna Murti

Dr. Krishna Murti


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Asian Pacific Journal of Tropical Biomedicine
Verified
Journal Article
Closed access
KMKrishna Murti
Krishna Murti
UKUpendra Kumar
Upendra Kumar
To establish the wound healing activity of aqueous and ethanolic extract of roots of Ficus racemosa (F. racemosa). Two models were performed to evaluate the wound healing activity i.e. incision and excision models. In incision model the parameter which was carried out was breaking strength of wounded skin. In excision model percentage wound contraction and period of epithelialization were established for both the extracts. Reference standard drug was povidone iodine ointment for comparison with other groups. From the observation in both two models, aqueous extract of F. racemosa was found to have greater wound healing activity in terms of breaking strength in incision model and percentage wound contraction, period of epithelialization in excision model than that of other groups. In conclusion, our findings suggest that aqueous extract of F. racemosa possesses better wound healing ability than the ethanolic extract.

7 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PGPavan Garapati
Pavan Garapati
BPBiplab Pal
Biplab Pal
NSNiyamat Ali Siddiqui
Niyamat Ali Siddiqui
SBSanjiva Bimal
Sanjiva Bimal
PDPradeep Das
Pradeep Das
KPKrishna Pandey
Krishna Pandey
Lesishmaniasis is a neglected tropical disease endemic in Bihar, India. Inappropriate health seeking behaviour of post kala-azar dermal leishmaniasis (PKDL) patients may increase the disease duration, severity and transmissibility. Simultaneously, lack of knowledge and perceived stigma may also increase the length of delay in receiving treatment. This ultimately effects the kala-azar elimination program. A cross sectional study was conducted in 120 confirmed PKDL patients, aged 18 years and older. Data related to knowledge and health seeking behaviour was collected by a pre-tested questionnaire. EMIC stigma scale was used for assessing the perceived stigma. Patients were personally interviewed after taking informed consent. Data analysis was done by using SPSS 16 software. The time between appearance of symptoms and first medical consultation (patient delay) ranged from 15 days to 5475 days (15 years) with a median of 285 days. The time between first medical consultations to onset of specific treatment (system delay) ranged from 2 to 5475 days with a median of 365 days. Many patients approached first to quacks (8.4%), homeopathic and ayurvedic practitioners (25.8%) upon recognition of symptoms. Majority of the patients (68.3%) had poor knowledge about PKDL and its vector. Type of skin lesions and gender had significant association with patient delay and system delay respectively (p<0.05). Distance to primary health centre (PHC) had significant association with patients delay as well as system delay (p<0.05). Patients with younger age, unmarried and polymorphic lesions had higher stigma (p<0.05). Patients with PKDL feel stigmatized in different areas. PKDL treatment delays were unacceptably high and patients had poor knowledge compounded with feelings of stigmatization. To reduce the delay, a system may be evolved to establish some sort of public-private collaboration, besides awareness programs should be tailored, and implemented for improving the patient education regarding the disease and its linkage with VL.

24 July 2017 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
BPBiplab Pal
Biplab Pal
KMKrishna Murti
Krishna Murti
NSNiyamat Ali Siddiqui
Niyamat Ali Siddiqui
PDPradeep Das
Pradeep Das
CLChandra Shekhar Lal
Chandra Shekhar Lal
KPKrishna Pandey
Krishna Pandey
Post kala-azar dermal leishmaniasis (PKDL) is a dermatological disorder caused by protozoal parasite Leishmania donovani. PKDL cases are thought to be a reservoir of parasites and may increase cases of visceral leishmaniasis. The disease is not life threatening but cosmetic disfigurement associated with it may impair the patients’ quality of life. This study aimed to assess the health related quality of life in patients with post kalaazar dermal leishmanasis for the first time. A total of 92 PKDL cases and 96 healthy participants filled out the questionnaires. The Dermatology Life Quality Index (DLQI) and SF 36 questionnaire were used to assess the quality of life. Data on socio-demographic and clinical features were also collected. The collected data were analyzed by using SPSS software (version 16), Student’s t-test, analysis of variance (ANOVA) was applied for comparison of means. PKDL patients experienced very large impact on their quality of life. The mean score of DLQI was 11.41. Highest impact was found in symptoms and feelings and lowest impact was observed for personal relationship domain. Patients below 20 years age group found to have lower quality of life. There was a significant difference in mean DLQI scores with regard to age and severity of lesions (P < 0.05). No significant difference was observed with respect to gender, duration and location of lesions (p > 0.05). PKDL significantly impaired the patient’s quality of life. Further studies to assess the impact of treatment on quality of life in these patients are recommended.

29 December 2023 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
Muhammed ShabilMuhammed Shabil
Muhammed Shabil
KMKrishna Murti
Krishna Murti
VKV Udaya Kumar
V Udaya Kumar
RKRishikesh Kumar
Rishikesh Kumar
NKNitesh Kumar
Nitesh Kumar
KPKrishna Pandey
Krishna Pandey
Background::: People with HIV (PLHIV) face increased cardiovascular disease (CVD) risk due to inflammation and immune activation. Aging further amplifies this risk. Limited data exist on CVD risk in older PLHIV in India despite 2.14 million PLHIV with higher CVD risk factors.Methods::: In a cross-sectional study in Bihar, India, 73 PLHIV and 30 control participants were enrolled. Demographics, social factors, clinical information, and CVD risk factors were collected. HbA1c levels and lipid profiles were analyzed, and 10-year CVD risk scores were calculated using the Framingham risk score (FRS) and Qrisk3. Quality of life (QoL) was assessed using WHOQOL- HIV-BREF.Results::: Results showed higher LDL levels in non-HIV older participants and higher HDL levels in younger PLHIV participants. BMI differed significantly, with higher BMI in non-HIV older individuals and lower BMI in younger PLHIV individuals. Older PLHIV participants had significantly higher mean FRS and Q-Risk scores compared to older non-PLHIV and younger PLHIV groups. Among older PLHIV participants, six had higher CVD risk per FRS, while none in the other groups were classified as high CVD risk. Psychological, social relations and spirituality domains were highly deteriorated in older PLHIV, scoring 44.48, 42.72, and 41.2, respectively. The physical domain scored 57.6, and the environment scored 52.72 in the WHOQOL-HIV bref.Conclusion::: In conclusion, older PLHIV in Bihar, India, face higher CVD risk compared to younger PLHIV and non-HIV individuals. FRS and Q-Risk scores effectively assessed CVD risk, identifying higher risk in older PLHIV. Age and BMI were significant predictors of high CVD risk. These findings emphasize CVD risk assessment and tailored management for older PLHIV. The QoL assessment findings indicate moderate deterioration in psychological, social relations, and spirituality domains among older PLHIV individuals. These results suggest greater challenges in psychological well-being, social interactions, and spirituality compared to the overall sample. Further research with larger samples and longitudinal designs is needed to confirm and extend these findings.

5 September 2023 in Current Pharmacology Reports
Verified
Journal Article
Closed access
Muhammed ShabilMuhammed Shabil
Muhammed Shabil
VKV Udaya Kumar
V Udaya Kumar
SDSameer Dhingra
Sameer Dhingra
VRV Ravichandiran
V Ravichandiran
VPVipan Kumar Parihar
Vipan Kumar Parihar
KMKrishna Murti
Krishna Murti

6 August 2022 in Current Pharmacology Reports
Verified
Journal Article
Closed access
PDF file
FSFathima A. S
Fathima A. S
MMMaxima Madhu
Maxima Madhu
VKV Udaya Kumar
V Udaya Kumar
SDSameer Dhingra
Sameer Dhingra
NKNitesh Kumar
Nitesh Kumar
KMKrishna Murti
Krishna Murti